Recent insider trends for Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on EBIO is anything to go by, investors should pay attention.
Institutions own 03.84% of Eleven Biotherapeutics, Inc. (EBIO)’s shares. The total value of these holdings, in millions, is $1. Among active positions in the latest quarter, 5 holders increased their positions by a total of 264568 shares, 15 holders decreased the positions by a total of 289516 shares, and 9 holders held their positions. This works out to a net decrease in ownership of 24948 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 3 holders initiated new positions by a total of 264463 shares and 7 holders exited their positions by a total of 186901 shares. This nets out to an increase of 77562 shares and is a bullish sign for EBIO.
Insider ownership increased by a total of 0 shares, which suggests that EBIO’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 1 sells, and ownership decreased by a net of 1399 shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)’s short interest is 1.45 million shares, or 16.67% of the float. This represents a decrease of -18% in the number of shares being shorted compared to the previous reading, and implies that investors felt less pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that EBIO is a sell, which implies that EBIO is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) is overvalued.